Nouvelles
19/09/2010
Vacature: Pharmacien d'Industrie Responsable
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
25/02/2008
Rhei Pharmaceuticals licenses Attental from MethaPharma (Vemedia Group) for distribution throughout Asia
RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental® throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.
27/07/2007
Acquisition MethaPharma (Belgique)
VEMEDIA PHARMA acquiert MethaPharma (Belgique) et effectue une augmentation de capital de 5 millions d’euros
01/05/2007
Accord europeen avec Pharmachemie
Vemedia conclut un accord europeen avec pharmachemie (Groupe TEVA).
19/09/2010
Vacature: Pharmacien d'Industrie Responsable
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
25/02/2008
Rhei Pharmaceuticals licenses Attental from MethaPharma (Vemedia Group) for distribution throughout Asia
RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental® throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.
27/07/2007
Acquisition MethaPharma (Belgique)
VEMEDIA PHARMA acquiert MethaPharma (Belgique) et effectue une augmentation de capital de 5 millions d’euros
01/05/2007
Accord europeen avec Pharmachemie
Vemedia conclut un accord europeen avec pharmachemie (Groupe TEVA).